RGC
ALXN

Roberts, Glore & Co’s Alexion Pharmaceuticals ALXN Stock Holding History

Roberts, Glore & Co’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,694
Closed -$679K – 205
2021
Q2 		$679K Hold
3,694
– – 0.2% 104
2021
Q1 		$565K Hold
3,694
– – 0.18% 115
2020
Q4 		$577K Buy
3,694
+65
+2% +$8.35K 0.19% 112
2020
Q3 		$415K Buy
3,629
+1,395
+62% +$150K 0.15% 127
2020
Q2 		$250K Buy
+2,234
New +$237K 0.1% 141
2020
Q1 		– Sell
-2,075
Closed -$224K – 184
2019
Q4 		$224K Buy
+2,075
New +$222K 0.09% 163

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Roberts, Glore & Co's ALXN Position: Q3 2021 in Review

Roberts, Glore & Co sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 3,694 shares — an estimated $679K sold.

Roberts, Glore & Co first reported a position in ALXN in Q4 2019 and held it in 6 quarters. The position peaked at $679K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Roberts, Glore & Co reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Roberts, Glore & Co sold 3,694 Alexion Pharmaceuticals shares in Q3 2021, an estimated $679K.
  • Roberts, Glore & Co first reported a position in Alexion Pharmaceuticals in Q4 2019 and held it in 6 quarters.
  • Roberts, Glore & Co's Alexion Pharmaceuticals position peaked at $679K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Roberts, Glore & Co's 13F filing for Q3 2021, filed 12 Nov 2021.